ATF4 and mTOR regulate metabolic reprogramming in TGF-β-treated lung fibroblasts.
Kun Woo D ShinM Volkan AtalayRengul Cetin-AtalayErin M O'LearyMariel E GlassJennifer C Houpy SzafranParker S WoodsAngelo Y MelitonObada R ShamaaYufeng TianGökhan M MutluRobert B HamanakaPublished in: bioRxiv : the preprint server for biology (2024)
Idiopathic pulmonary fibrosis is a fatal disease characterized by the TGF-β-dependent activation of lung fibroblasts, leading to excessive deposition of collagen proteins and progressive replacement of healthy lung with scar tissue. We and others have shown that fibroblast activation is supported by metabolic reprogramming, including the upregulation of the de novo synthesis of glycine, the most abundant amino acid found in collagen protein. How fibroblast metabolic reprogramming is regulated downstream of TGF-β is incompletely understood. We and others have shown that TGF-β-mediated activation of the Mechanistic Target of Rapamycin Complex 1 (mTORC1) and downstream upregulation of Activating Transcription Factor 4 (ATF4) promote increased expression of the enzymes required for de novo glycine synthesis; however, whether mTOR and ATF4 regulate other metabolic pathways in lung fibroblasts has not been explored. Here, we used RNA sequencing to determine how both ATF4 and mTOR regulate gene expression in human lung fibroblasts following TGF-β. We found that ATF4 primarily regulates enzymes and transporters involved in amino acid homeostasis as well as aminoacyl-tRNA synthetases. mTOR inhibition resulted not only in the loss of ATF4 target gene expression, but also in the reduced expression of glycolytic enzymes and mitochondrial electron transport chain subunits. Analysis of TGF-β-induced changes in cellular metabolite levels confirmed that ATF4 regulates amino acid homeostasis in lung fibroblasts while mTOR also regulates glycolytic and TCA cycle metabolites. We further analyzed publicly available single cell RNAseq data sets and found increased expression of ATF4 and mTOR metabolic targets in pathologic fibroblast populations from the lungs of IPF patients. Our results provide insight into the mechanisms of metabolic reprogramming in lung fibroblasts and highlight novel ATF4 and mTOR-dependent pathways that may be targeted to inhibit fibrotic processes.
Keyphrases
- transcription factor
- endoplasmic reticulum stress
- idiopathic pulmonary fibrosis
- amino acid
- cell proliferation
- poor prognosis
- transforming growth factor
- gene expression
- single cell
- extracellular matrix
- dna binding
- end stage renal disease
- wound healing
- dna methylation
- newly diagnosed
- multiple sclerosis
- binding protein
- chronic kidney disease
- epithelial mesenchymal transition
- genome wide identification
- machine learning
- ejection fraction
- rna seq
- systemic sclerosis
- radiation therapy
- cancer therapy
- physical activity
- weight gain
- drug delivery
- weight loss
- rectal cancer